US 12,465,646 B2
Linkers
Richard Raz, London (GB); Matthew Wood, Oxford (GB); Caroline Godfrey, Wolvercote (GB); Graham McClorey, Oxford (GB); Subhashis Banerjee, Kolkata (IN); Michael Gait, Cambridge (GB); Miguel Varela, Oxford (GB); and Ashling Holland, Oxford (GB)
Assigned to Oxford University Innovation Limited, Oxford (GB); and United Kingdom Research and Innovation, Swindon (GB)
Appl. No. 17/311,062
Filed by Oxford University Innovation Limited, Oxford (GB); and United Kingdom Research and Innovation, Swindon (GB)
PCT Filed Dec. 6, 2019, PCT No. PCT/GB2019/053445
§ 371(c)(1), (2) Date Jun. 4, 2021,
PCT Pub. No. WO2020/115494, PCT Pub. Date Jun. 11, 2020.
Claims priority of application No. 1820020 (GB), filed on Dec. 7, 2018; and application No. 1911405 (GB), filed on Aug. 9, 2019.
Prior Publication US 2022/0125934 A1, Apr. 28, 2022
Int. Cl. A61K 47/54 (2017.01); A61K 47/64 (2017.01)
CPC A61K 47/542 (2017.08) [A61K 47/64 (2017.08); A61K 47/645 (2017.08)] 8 Claims
 
1. A conjugate or a pharmaceutically acceptable salt or solvate thereof of the structure

OG Complex Work Unit Chemistry
wherein the carrier is a peptide consisting of the sequence RBRRBRFQILYBRBR (SEQ ID NO: 70), wherein the peptide is N-acetylated, and
wherein the therapeutic molecule is an antisense oligonucleotide consisting of the sequence 5′-CAGCAGCAGCAGCAGCAGCAG-3′ (SEQ ID NO: 81), wherein the antisense oligonucleotide is a PMO.